Compare OMH & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 2.6M |
| IPO Year | 2023 | N/A |
| Metric | OMH | GTBP |
|---|---|---|
| Price | $0.80 | $0.76 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 1.2M |
| Earning Date | 04-17-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.86 | N/A |
| 52 Week Low | $0.59 | $0.54 |
| 52 Week High | $5.10 | $4.10 |
| Indicator | OMH | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 56.57 |
| Support Level | $0.79 | $0.63 |
| Resistance Level | $1.15 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.09 | 75.73 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.